InvestorsHub Logo
Followers 138
Posts 22891
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Monday, 05/16/2022 9:35:59 PM

Monday, May 16, 2022 9:35:59 PM

Post# of 660

In April 2022, we announced that it has received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the NDA for our AXS-05 product candidate for the treatment of major depressive disorder.

Based on this interaction, we anticipate potential FDA action on the NDA in the second quarter of 2022.



https://www.sec.gov/ix?doc=/Archives/edgar/data/1579428/000095017022006901/axsm-20220331.htm

Good luck and GOD bless,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AXSM News